Baird
Neurocrine Biosciences (NBIX): Physician Survey Indicates Positive Surprise May Be Coming - Baird
Baird analyst, Brian Skorney, reiterated his Outperform rating on shares of Neurocrine Bio. (NASDAQ: NBIX) after surveying 30 physicians on their overall impressions of Ingrezza, potential for use in TD, competition with Teva's Austedo, and use of Ingrezza.
The analyst stated "though we continue to expect the Ingrezza launch to be rather slow and steady, it looks like TD may be a much more active indication than we originally expected.After being shocked by 2Q17 sales numbers, based on these results, we wouldn't be surprised if 3Q17 numbers are even more impressive".